Novel Glutamine Antagonist JHU395 Suppresses MYC-Driven Medulloblastoma Growth and Induces ApoptosisKhoa Pham, Eric H. Raabe, Micah J. Maxwell et al.|Journal of Neuropathology & Experimental Neurology|2021Cited by 27
Comprehensive Metabolic Profiling of MYC-Amplified Medulloblastoma Tumors Reveals Key Dependencies on Amino Acid, Tricarboxylic Acid and Hexosamine PathwaysKhoa Pham, Eric H. Raabe, Allison R. Hanaford et al.|Cancers|2022Cited by 21
Dual mTORC1/2 inhibition compromises cell defenses against exogenous stress potentiating Obatoclax-induced cytotoxicity in atypical teratoid/rhabdoid tumorsAshlyn Parkhurst, Jeffrey Rubens, Harpreet Kaur et al.|Cell Death and Disease|2022Cited by 8
Unbiased Proteomic and Phosphoproteomic Analysis Identifies Response Signatures and Novel Susceptibilities After Combined MEK and mTOR Inhibition in BRAFV600E Mutant GliomaMicah J. Maxwell, Eric H. Raabe, Antje Arnold et al.|Molecular & Cellular Proteomics|2021Cited by 7
OTME-9. Comprehensive Metabolic Profiling Of high MYC Medulloblastoma Reveals Key Differences Between In <i>Vitro</i> And In <i>Vivo</i> Glucose And Glutamine UsageKhoa Pham, Eric H. Raabe, Brad Poore et al.|Neuro-Oncology Advances|2021Cited by 1